Cargando…

The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity

Encephalopathy of prematurity (EoP) is a major cause of morbidity in preterm neonates, causing neurodevelopmental adversities that can lead to lifelong impairments. Preterm birth‐related insults, such as cerebral oxygen fluctuations and perinatal inflammation, are believed to negatively impact brain...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaes, Josine E. G., Brandt, Myrna J. V., Wanders, Nikki, Benders, Manon J. N. L., de Theije, Caroline G. M., Gressens, Pierre, Nijboer, Cora H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246971/
https://www.ncbi.nlm.nih.gov/pubmed/33595855
http://dx.doi.org/10.1002/glia.23939
_version_ 1783716424219361280
author Vaes, Josine E. G.
Brandt, Myrna J. V.
Wanders, Nikki
Benders, Manon J. N. L.
de Theije, Caroline G. M.
Gressens, Pierre
Nijboer, Cora H.
author_facet Vaes, Josine E. G.
Brandt, Myrna J. V.
Wanders, Nikki
Benders, Manon J. N. L.
de Theije, Caroline G. M.
Gressens, Pierre
Nijboer, Cora H.
author_sort Vaes, Josine E. G.
collection PubMed
description Encephalopathy of prematurity (EoP) is a major cause of morbidity in preterm neonates, causing neurodevelopmental adversities that can lead to lifelong impairments. Preterm birth‐related insults, such as cerebral oxygen fluctuations and perinatal inflammation, are believed to negatively impact brain development, leading to a range of brain abnormalities. Diffuse white matter injury is a major hallmark of EoP and characterized by widespread hypomyelination, the result of disturbances in oligodendrocyte lineage development. At present, there are no treatment options available, despite the enormous burden of EoP on patients, their families, and society. Over the years, research in the field of neonatal brain injury and other white matter pathologies has led to the identification of several promising trophic factors and cytokines that contribute to the survival and maturation of oligodendrocytes, and/or dampening neuroinflammation. In this review, we discuss the current literature on selected factors and their therapeutic potential to combat EoP, covering a wide range of in vitro, preclinical and clinical studies. Furthermore, we offer a future perspective on the translatability of these factors into clinical practice.
format Online
Article
Text
id pubmed-8246971
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-82469712021-07-02 The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity Vaes, Josine E. G. Brandt, Myrna J. V. Wanders, Nikki Benders, Manon J. N. L. de Theije, Caroline G. M. Gressens, Pierre Nijboer, Cora H. Glia Review Articles Encephalopathy of prematurity (EoP) is a major cause of morbidity in preterm neonates, causing neurodevelopmental adversities that can lead to lifelong impairments. Preterm birth‐related insults, such as cerebral oxygen fluctuations and perinatal inflammation, are believed to negatively impact brain development, leading to a range of brain abnormalities. Diffuse white matter injury is a major hallmark of EoP and characterized by widespread hypomyelination, the result of disturbances in oligodendrocyte lineage development. At present, there are no treatment options available, despite the enormous burden of EoP on patients, their families, and society. Over the years, research in the field of neonatal brain injury and other white matter pathologies has led to the identification of several promising trophic factors and cytokines that contribute to the survival and maturation of oligodendrocytes, and/or dampening neuroinflammation. In this review, we discuss the current literature on selected factors and their therapeutic potential to combat EoP, covering a wide range of in vitro, preclinical and clinical studies. Furthermore, we offer a future perspective on the translatability of these factors into clinical practice. John Wiley & Sons, Inc. 2020-11-30 2021-06 /pmc/articles/PMC8246971/ /pubmed/33595855 http://dx.doi.org/10.1002/glia.23939 Text en © 2020 The Authors. GLIA published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Vaes, Josine E. G.
Brandt, Myrna J. V.
Wanders, Nikki
Benders, Manon J. N. L.
de Theije, Caroline G. M.
Gressens, Pierre
Nijboer, Cora H.
The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity
title The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity
title_full The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity
title_fullStr The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity
title_full_unstemmed The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity
title_short The impact of trophic and immunomodulatory factors on oligodendrocyte maturation: Potential treatments for encephalopathy of prematurity
title_sort impact of trophic and immunomodulatory factors on oligodendrocyte maturation: potential treatments for encephalopathy of prematurity
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246971/
https://www.ncbi.nlm.nih.gov/pubmed/33595855
http://dx.doi.org/10.1002/glia.23939
work_keys_str_mv AT vaesjosineeg theimpactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity
AT brandtmyrnajv theimpactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity
AT wandersnikki theimpactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity
AT bendersmanonjnl theimpactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity
AT detheijecarolinegm theimpactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity
AT gressenspierre theimpactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity
AT nijboercorah theimpactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity
AT vaesjosineeg impactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity
AT brandtmyrnajv impactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity
AT wandersnikki impactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity
AT bendersmanonjnl impactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity
AT detheijecarolinegm impactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity
AT gressenspierre impactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity
AT nijboercorah impactoftrophicandimmunomodulatoryfactorsonoligodendrocytematurationpotentialtreatmentsforencephalopathyofprematurity